TICAM-1/TRIF associates with Act1 and suppresses IL-17 receptor–mediated inflammatory responses

TICAM-1 (also called TRIF) is the sole adaptor of TLR3 that recognizes double-stranded RNA. Here, we report that TICAM-1 is involved not only in TLR3 signaling but also in the cytokine receptor IL-17RA signaling. We found that TICAM-1 bound to IL-17R adaptor Act1 to inhibit the interaction between I...

Full description

Saved in:
Bibliographic Details
Published inLife science alliance Vol. 5; no. 2; p. e202101181
Main Authors Miyashita, Yusuke, Kouwaki, Takahisa, Tsukamoto, Hirotake, Okamoto, Masaaki, Nakamura, Kimitoshi, Oshiumi, Hiroyuki
Format Journal Article
LanguageEnglish
Published United States Life Science Alliance LLC 01.02.2022
Subjects
Adaptor Proteins, Vesicular Transport - genetics
Adaptor Proteins, Vesicular Transport - metabolism
Animals
Autoimmune Diseases - etiology
Autoimmune Diseases - metabolism
Autoimmunity
Biomarkers
Connexin 43 - metabolism
Disease Susceptibility
Gene Knockdown Techniques
Inflammation - etiology
Inflammation - metabolism
Mice
Peptide Fragments - metabolism
Receptors, Interleukin - metabolism
Signal Transduction
Online AccessGet full text
ISSN2575-1077
2575-1077
DOI10.26508/lsa.202101181

Cover

Abstract TICAM-1 (also called TRIF) is the sole adaptor of TLR3 that recognizes double-stranded RNA. Here, we report that TICAM-1 is involved not only in TLR3 signaling but also in the cytokine receptor IL-17RA signaling. We found that TICAM-1 bound to IL-17R adaptor Act1 to inhibit the interaction between IL-17RA and Act1. Interestingly, TICAM-1 knockout promoted IL-17RA/Act1 interaction and increased IL-17A–mediated activation of NF-κB and MAP kinases, leading to enhanced expression of inflammatory cytokines and chemokines upon IL-17A stimulation. Moreover, Ticam-1 knockout augmented IL-17A–mediated CXCL1 and CXCL2 expression in vivo, resulting in accumulation of myeloid cells. Furthermore, Ticam-1 knockout enhanced delayed type hypersensitivity and exacerbated experimental autoimmune encephalomyelitis. Ticam-1 knockout promoted accumulation of myeloid and lymphoid cells in the spinal cord of EAE-induced mice. Collectively, these data indicate that TICAM-1 inhibits the interaction between IL-17RA and Act1 and functions as a negative regulator in IL-17A–mediated inflammatory responses.
AbstractList TICAM-1/TRIF, a TLR3 adaptor molecule, associates with Act1 to inhibit the interaction between IL-17RA and Act1, resulting in attenuated IL-17-mediated inflammatory responses. TICAM-1 (also called TRIF) is the sole adaptor of TLR3 that recognizes double-stranded RNA. Here, we report that TICAM-1 is involved not only in TLR3 signaling but also in the cytokine receptor IL-17RA signaling. We found that TICAM-1 bound to IL-17R adaptor Act1 to inhibit the interaction between IL-17RA and Act1. Interestingly, TICAM-1 knockout promoted IL-17RA/Act1 interaction and increased IL-17A–mediated activation of NF-κB and MAP kinases, leading to enhanced expression of inflammatory cytokines and chemokines upon IL-17A stimulation. Moreover, Ticam-1 knockout augmented IL-17A–mediated CXCL1 and CXCL2 expression in vivo, resulting in accumulation of myeloid cells. Furthermore, Ticam-1 knockout enhanced delayed type hypersensitivity and exacerbated experimental autoimmune encephalomyelitis. Ticam-1 knockout promoted accumulation of myeloid and lymphoid cells in the spinal cord of EAE-induced mice. Collectively, these data indicate that TICAM-1 inhibits the interaction between IL-17RA and Act1 and functions as a negative regulator in IL-17A–mediated inflammatory responses.
TICAM-1 (also called TRIF) is the sole adaptor of TLR3 that recognizes double-stranded RNA. Here, we report that TICAM-1 is involved not only in TLR3 signaling but also in the cytokine receptor IL-17RA signaling. We found that TICAM-1 bound to IL-17R adaptor Act1 to inhibit the interaction between IL-17RA and Act1. Interestingly, knockout promoted IL-17RA/Act1 interaction and increased IL-17A-mediated activation of NF-κB and MAP kinases, leading to enhanced expression of inflammatory cytokines and chemokines upon IL-17A stimulation. Moreover, knockout augmented IL-17A-mediated CXCL1 and CXCL2 expression in vivo, resulting in accumulation of myeloid cells. Furthermore, knockout enhanced delayed type hypersensitivity and exacerbated experimental autoimmune encephalomyelitis. knockout promoted accumulation of myeloid and lymphoid cells in the spinal cord of EAE-induced mice. Collectively, these data indicate that TICAM-1 inhibits the interaction between IL-17RA and Act1 and functions as a negative regulator in IL-17A-mediated inflammatory responses.
TICAM-1 (also called TRIF) is the sole adaptor of TLR3 that recognizes double-stranded RNA. Here, we report that TICAM-1 is involved not only in TLR3 signaling but also in the cytokine receptor IL-17RA signaling. We found that TICAM-1 bound to IL-17R adaptor Act1 to inhibit the interaction between IL-17RA and Act1. Interestingly, TICAM-1 knockout promoted IL-17RA/Act1 interaction and increased IL-17A–mediated activation of NF-κB and MAP kinases, leading to enhanced expression of inflammatory cytokines and chemokines upon IL-17A stimulation. Moreover, Ticam-1 knockout augmented IL-17A–mediated CXCL1 and CXCL2 expression in vivo, resulting in accumulation of myeloid cells. Furthermore, Ticam-1 knockout enhanced delayed type hypersensitivity and exacerbated experimental autoimmune encephalomyelitis. Ticam-1 knockout promoted accumulation of myeloid and lymphoid cells in the spinal cord of EAE-induced mice. Collectively, these data indicate that TICAM-1 inhibits the interaction between IL-17RA and Act1 and functions as a negative regulator in IL-17A–mediated inflammatory responses.
TICAM-1 (also called TRIF) is the sole adaptor of TLR3 that recognizes double-stranded RNA. Here, we report that TICAM-1 is involved not only in TLR3 signaling but also in the cytokine receptor IL-17RA signaling. We found that TICAM-1 bound to IL-17R adaptor Act1 to inhibit the interaction between IL-17RA and Act1. Interestingly, TICAM-1 knockout promoted IL-17RA/Act1 interaction and increased IL-17A-mediated activation of NF-κB and MAP kinases, leading to enhanced expression of inflammatory cytokines and chemokines upon IL-17A stimulation. Moreover, Ticam-1 knockout augmented IL-17A-mediated CXCL1 and CXCL2 expression in vivo, resulting in accumulation of myeloid cells. Furthermore, Ticam-1 knockout enhanced delayed type hypersensitivity and exacerbated experimental autoimmune encephalomyelitis. Ticam-1 knockout promoted accumulation of myeloid and lymphoid cells in the spinal cord of EAE-induced mice. Collectively, these data indicate that TICAM-1 inhibits the interaction between IL-17RA and Act1 and functions as a negative regulator in IL-17A-mediated inflammatory responses.TICAM-1 (also called TRIF) is the sole adaptor of TLR3 that recognizes double-stranded RNA. Here, we report that TICAM-1 is involved not only in TLR3 signaling but also in the cytokine receptor IL-17RA signaling. We found that TICAM-1 bound to IL-17R adaptor Act1 to inhibit the interaction between IL-17RA and Act1. Interestingly, TICAM-1 knockout promoted IL-17RA/Act1 interaction and increased IL-17A-mediated activation of NF-κB and MAP kinases, leading to enhanced expression of inflammatory cytokines and chemokines upon IL-17A stimulation. Moreover, Ticam-1 knockout augmented IL-17A-mediated CXCL1 and CXCL2 expression in vivo, resulting in accumulation of myeloid cells. Furthermore, Ticam-1 knockout enhanced delayed type hypersensitivity and exacerbated experimental autoimmune encephalomyelitis. Ticam-1 knockout promoted accumulation of myeloid and lymphoid cells in the spinal cord of EAE-induced mice. Collectively, these data indicate that TICAM-1 inhibits the interaction between IL-17RA and Act1 and functions as a negative regulator in IL-17A-mediated inflammatory responses.
Author Tsukamoto, Hirotake
Okamoto, Masaaki
Miyashita, Yusuke
Oshiumi, Hiroyuki
Nakamura, Kimitoshi
Kouwaki, Takahisa
AuthorAffiliation 2 Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan
1 Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan
3 Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
AuthorAffiliation_xml – name: 2 Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan
– name: 3 Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
– name: 1 Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan
Author_xml – sequence: 1
  givenname: Yusuke
  orcidid: 0000-0002-4696-6834
  surname: Miyashita
  fullname: Miyashita, Yusuke
  organization: Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan, Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan
– sequence: 2
  givenname: Takahisa
  surname: Kouwaki
  fullname: Kouwaki, Takahisa
  organization: Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan
– sequence: 3
  givenname: Hirotake
  orcidid: 0000-0003-3214-1652
  surname: Tsukamoto
  fullname: Tsukamoto, Hirotake
  organization: Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan, Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
– sequence: 4
  givenname: Masaaki
  orcidid: 0000-0001-7689-2939
  surname: Okamoto
  fullname: Okamoto, Masaaki
  organization: Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan
– sequence: 5
  givenname: Kimitoshi
  orcidid: 0000-0003-4903-2428
  surname: Nakamura
  fullname: Nakamura, Kimitoshi
  organization: Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan
– sequence: 6
  givenname: Hiroyuki
  orcidid: 0000-0003-1567-8722
  surname: Oshiumi
  fullname: Oshiumi, Hiroyuki
  organization: Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34819358$$D View this record in MEDLINE/PubMed
BookMark eNp1UUtLAzEQDqL4qF49yh69bJ1kN9n0Ioj4KFQEqeeQpFmN7G7WJFV68z_4D_0lRqtFBWEgw8z3GPLtoPXOdQahfQxDwijwoybIIQGCAWOO19A2oRXNMVTV-o9-C-2F8AAAJFVJy020VZQcjwrKt5Gcjk9PrnJ8NL0Zn2cyBKetjCZkzzbeZyc64kx2syzM-96bENJiPMlxlXmjTR-df3t5bc3sgzLLbFc3sm1lGi8SIPSuS4RdtFHLJpi9r3eAbs_PpqeX-eT6InlPck0BYs6V4bgqWA11BZVWShOqgCquKC9LZsp6RClIwEwRzhWZGVJLMgLFGShTyWKAjpe6_Vylk7TpopeN6L1tpV8IJ634vensvbhzT4IzzGjBk8Dhl4B3j3MTomht0KZpZGfcPAjCgLCywIwk6MFPr5XJ978mwHAJ0N6F4E29gmAQn9mJlJ1YZZcI5R-CtlFG6z5utc1_tHf_e54a
CitedBy_id crossref_primary_10_1016_j_jid_2022_02_016
crossref_primary_10_3389_fneur_2023_1284304
crossref_primary_10_1016_j_taap_2022_116259
crossref_primary_10_1007_s00018_025_05631_x
crossref_primary_10_1007_s12031_024_02209_3
crossref_primary_10_1159_000541908
crossref_primary_10_1002_clt2_12334
crossref_primary_10_3390_ijms232315215
crossref_primary_10_1080_08923973_2024_2330642
Cites_doi 10.1073/pnas.0611589104
10.1152/ajpgi.00494.2001
10.1016/j.immuni.2020.01.002
10.1111/j.1749-6632.2010.05825.x
10.1016/S1074-7613(00)80596-8
10.1016/j.immuni.2008.11.009
10.1038/ni886
10.1016/j.cellsig.2010.11.022
10.4049/jimmunol.169.12.6668
10.1038/ni.3558
10.1074/jbc.M801013200
10.1016/j.bbrc.2018.04.035
10.1038/nature03326
10.1016/s2213-2600(20)30076-x
10.1111/j.1365-2133.2012.11099.x
10.1172/JCI33342
10.1016/S1074-7613(02)00391-6
10.1038/nrmicro.2016.45
10.1038/s41590-018-0071-9
10.1038/jid.2014.383
10.1074/jbc.M305820200
10.1038/nm1140
10.1016/j.immuni.2019.03.021
10.1074/jbc.273.20.12203
10.1038/nri1391
10.1126/scitranslmed.abd5487
10.1371/journal.pone.0083639
10.1084/jem.20031023
10.3389/fimmu.2019.02202
10.1016/j.cyto.2020.155323
10.1016/j.cell.2012.04.042
10.1146/annurev.immunol.18.1.621
10.1016/j.immuni.2008.07.018
10.1016/j.chom.2016.08.002
10.4049/jimmunol.0900995
10.1080/2162402X.2016.1188244
10.1038/ncomms7669
10.1126/science.abd4570
10.1111/imr.12091
10.1038/s41590-019-0514-y
10.1111/cei.12376
10.1038/s41586-019-1844-5
10.1016/j.immuni.2011.05.006
10.1016/S0968-0004(03)00067-7
10.4049/jimmunol.1101503
10.1126/sciimmunol.abe1670
10.1038/ni1439
10.1128/mBio.00638-15
10.1038/nprot.2013.143
ContentType Journal Article
Copyright 2021 Miyashita et al.
2021 Miyashita et al. 2021
Copyright_xml – notice: 2021 Miyashita et al.
– notice: 2021 Miyashita et al. 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.26508/lsa.202101181
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
DocumentTitleAlternate TICAM-1 is a negative regulator of IL-17RA signaling
EISSN 2575-1077
ExternalDocumentID PMC8616538
34819358
10_26508_lsa_202101181
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ;
– fundername: ;
  grantid: JPH03480 and 19H03480
GroupedDBID 53G
AAYXX
ADBBV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCNDV
CITATION
EBS
EMOBN
FRP
GROUPED_DOAJ
HK~
HYE
M~E
OK1
PGMZT
RPM
CGR
CUY
CVF
ECM
EIF
NPM
RHF
7X8
5PM
ID FETCH-LOGICAL-c500t-8be81736f0f707cbbc25b05b8b58446e4f9550a016b288b2de2fa290b860be7a3
ISSN 2575-1077
IngestDate Thu Aug 21 18:29:29 EDT 2025
Fri Jul 11 01:35:11 EDT 2025
Thu Jan 02 22:55:22 EST 2025
Tue Jul 01 02:54:43 EDT 2025
Thu Apr 24 22:55:10 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License 2021 Miyashita et al.
This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c500t-8be81736f0f707cbbc25b05b8b58446e4f9550a016b288b2de2fa290b860be7a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-3214-1652
0000-0003-4903-2428
0000-0003-1567-8722
0000-0001-7689-2939
0000-0002-4696-6834
OpenAccessLink http://dx.doi.org/10.26508/lsa.202101181
PMID 34819358
PQID 2602643162
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8616538
proquest_miscellaneous_2602643162
pubmed_primary_34819358
crossref_primary_10_26508_lsa_202101181
crossref_citationtrail_10_26508_lsa_202101181
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-02-01
PublicationDateYYYYMMDD 2022-02-01
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Life science alliance
PublicationTitleAlternate Life Sci Alliance
PublicationYear 2022
Publisher Life Science Alliance LLC
Publisher_xml – name: Life Science Alliance LLC
References 2021112410050558000_5.2.e202101181.8
2021112410050558000_5.2.e202101181.9
2021112410050558000_5.2.e202101181.15
2021112410050558000_5.2.e202101181.16
2021112410050558000_5.2.e202101181.17
2021112410050558000_5.2.e202101181.18
2021112410050558000_5.2.e202101181.11
2021112410050558000_5.2.e202101181.12
2021112410050558000_5.2.e202101181.13
2021112410050558000_5.2.e202101181.14
2021112410050558000_5.2.e202101181.10
2021112410050558000_5.2.e202101181.48
2021112410050558000_5.2.e202101181.49
2021112410050558000_5.2.e202101181.44
2021112410050558000_5.2.e202101181.45
2021112410050558000_5.2.e202101181.46
2021112410050558000_5.2.e202101181.47
2021112410050558000_5.2.e202101181.2
2021112410050558000_5.2.e202101181.40
2021112410050558000_5.2.e202101181.3
2021112410050558000_5.2.e202101181.41
2021112410050558000_5.2.e202101181.42
2021112410050558000_5.2.e202101181.1
2021112410050558000_5.2.e202101181.43
2021112410050558000_5.2.e202101181.6
2021112410050558000_5.2.e202101181.7
2021112410050558000_5.2.e202101181.4
2021112410050558000_5.2.e202101181.5
2021112410050558000_5.2.e202101181.37
2021112410050558000_5.2.e202101181.38
2021112410050558000_5.2.e202101181.39
2021112410050558000_5.2.e202101181.33
2021112410050558000_5.2.e202101181.34
2021112410050558000_5.2.e202101181.35
2021112410050558000_5.2.e202101181.36
2021112410050558000_5.2.e202101181.30
2021112410050558000_5.2.e202101181.31
2021112410050558000_5.2.e202101181.32
2021112410050558000_5.2.e202101181.19
2021112410050558000_5.2.e202101181.26
2021112410050558000_5.2.e202101181.27
2021112410050558000_5.2.e202101181.28
2021112410050558000_5.2.e202101181.29
2021112410050558000_5.2.e202101181.22
2021112410050558000_5.2.e202101181.23
2021112410050558000_5.2.e202101181.24
2021112410050558000_5.2.e202101181.25
2021112410050558000_5.2.e202101181.20
2021112410050558000_5.2.e202101181.21
References_xml – ident: 2021112410050558000_5.2.e202101181.23
  doi: 10.1073/pnas.0611589104
– ident: 2021112410050558000_5.2.e202101181.16
  doi: 10.1152/ajpgi.00494.2001
– ident: 2021112410050558000_5.2.e202101181.25
  doi: 10.1016/j.immuni.2020.01.002
– ident: 2021112410050558000_5.2.e202101181.18
  doi: 10.1111/j.1749-6632.2010.05825.x
– ident: 2021112410050558000_5.2.e202101181.2
  doi: 10.1016/S1074-7613(00)80596-8
– ident: 2021112410050558000_5.2.e202101181.19
  doi: 10.1016/j.immuni.2008.11.009
– ident: 2021112410050558000_5.2.e202101181.31
  doi: 10.1038/ni886
– ident: 2021112410050558000_5.2.e202101181.7
  doi: 10.1016/j.cellsig.2010.11.022
– ident: 2021112410050558000_5.2.e202101181.48
  doi: 10.4049/jimmunol.169.12.6668
– ident: 2021112410050558000_5.2.e202101181.8
  doi: 10.1038/ni.3558
– ident: 2021112410050558000_5.2.e202101181.11
  doi: 10.1074/jbc.M801013200
– ident: 2021112410050558000_5.2.e202101181.42
  doi: 10.1016/j.bbrc.2018.04.035
– ident: 2021112410050558000_5.2.e202101181.40
  doi: 10.1038/nature03326
– ident: 2021112410050558000_5.2.e202101181.47
  doi: 10.1016/s2213-2600(20)30076-x
– ident: 2021112410050558000_5.2.e202101181.14
  doi: 10.1111/j.1365-2133.2012.11099.x
– ident: 2021112410050558000_5.2.e202101181.15
  doi: 10.1172/JCI33342
– ident: 2021112410050558000_5.2.e202101181.27
  doi: 10.1016/S1074-7613(02)00391-6
– ident: 2021112410050558000_5.2.e202101181.6
  doi: 10.1038/nrmicro.2016.45
– ident: 2021112410050558000_5.2.e202101181.17
  doi: 10.1038/s41590-018-0071-9
– ident: 2021112410050558000_5.2.e202101181.46
  doi: 10.1038/jid.2014.383
– ident: 2021112410050558000_5.2.e202101181.33
  doi: 10.1074/jbc.M305820200
– ident: 2021112410050558000_5.2.e202101181.44
  doi: 10.1038/nm1140
– ident: 2021112410050558000_5.2.e202101181.24
  doi: 10.1016/j.immuni.2019.03.021
– ident: 2021112410050558000_5.2.e202101181.5
  doi: 10.1074/jbc.273.20.12203
– ident: 2021112410050558000_5.2.e202101181.3
  doi: 10.1038/nri1391
– ident: 2021112410050558000_5.2.e202101181.35
  doi: 10.1126/scitranslmed.abd5487
– ident: 2021112410050558000_5.2.e202101181.41
  doi: 10.1371/journal.pone.0083639
– ident: 2021112410050558000_5.2.e202101181.10
  doi: 10.1084/jem.20031023
– ident: 2021112410050558000_5.2.e202101181.38
  doi: 10.3389/fimmu.2019.02202
– ident: 2021112410050558000_5.2.e202101181.13
  doi: 10.1016/j.cyto.2020.155323
– ident: 2021112410050558000_5.2.e202101181.1
  doi: 10.1016/j.cell.2012.04.042
– ident: 2021112410050558000_5.2.e202101181.20
  doi: 10.1146/annurev.immunol.18.1.621
– ident: 2021112410050558000_5.2.e202101181.30
  doi: 10.1016/j.immuni.2008.07.018
– ident: 2021112410050558000_5.2.e202101181.45
  doi: 10.1016/j.chom.2016.08.002
– ident: 2021112410050558000_5.2.e202101181.9
  doi: 10.4049/jimmunol.0900995
– ident: 2021112410050558000_5.2.e202101181.4
  doi: 10.1080/2162402X.2016.1188244
– ident: 2021112410050558000_5.2.e202101181.26
  doi: 10.1038/ncomms7669
– ident: 2021112410050558000_5.2.e202101181.49
  doi: 10.1126/science.abd4570
– ident: 2021112410050558000_5.2.e202101181.12
  doi: 10.1111/imr.12091
– ident: 2021112410050558000_5.2.e202101181.22
  doi: 10.1038/s41590-019-0514-y
– ident: 2021112410050558000_5.2.e202101181.39
  doi: 10.1111/cei.12376
– ident: 2021112410050558000_5.2.e202101181.28
  doi: 10.1038/s41586-019-1844-5
– ident: 2021112410050558000_5.2.e202101181.21
  doi: 10.1016/j.immuni.2011.05.006
– ident: 2021112410050558000_5.2.e202101181.29
  doi: 10.1016/S0968-0004(03)00067-7
– ident: 2021112410050558000_5.2.e202101181.32
  doi: 10.4049/jimmunol.1101503
– ident: 2021112410050558000_5.2.e202101181.34
  doi: 10.1126/sciimmunol.abe1670
– ident: 2021112410050558000_5.2.e202101181.36
  doi: 10.1038/ni1439
– ident: 2021112410050558000_5.2.e202101181.43
  doi: 10.1128/mBio.00638-15
– ident: 2021112410050558000_5.2.e202101181.37
  doi: 10.1038/nprot.2013.143
SSID ssj0002002454
Score 2.2391388
Snippet TICAM-1 (also called TRIF) is the sole adaptor of TLR3 that recognizes double-stranded RNA. Here, we report that TICAM-1 is involved not only in TLR3 signaling...
TICAM-1/TRIF, a TLR3 adaptor molecule, associates with Act1 to inhibit the interaction between IL-17RA and Act1, resulting in attenuated IL-17-mediated...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e202101181
SubjectTerms Adaptor Proteins, Vesicular Transport - genetics
Adaptor Proteins, Vesicular Transport - metabolism
Animals
Autoimmune Diseases - etiology
Autoimmune Diseases - metabolism
Autoimmunity
Biomarkers
Connexin 43 - metabolism
Disease Susceptibility
Gene Knockdown Techniques
Inflammation - etiology
Inflammation - metabolism
Mice
Peptide Fragments - metabolism
Receptors, Interleukin - metabolism
Signal Transduction
Title TICAM-1/TRIF associates with Act1 and suppresses IL-17 receptor–mediated inflammatory responses
URI https://www.ncbi.nlm.nih.gov/pubmed/34819358
https://www.proquest.com/docview/2602643162
https://pubmed.ncbi.nlm.nih.gov/PMC8616538
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9NAFB7qCrIv4nrbemMEQaXEnaS5Ppbi0qpVkS6sT-VMesLW3U1LkyD65B_wyX_oL_HMZHLTFXRfQslMJmG-r2fOmXMZxp5AEAPSQmctAYTlYuRaEXjSspMIZaQSEjyV4Dx760-O3FfH3nGv970VtVTk8kX89cK8ksugSvcIV5Ul-x_I1oPSDfpN-NKVEKbrv2E8HY9mlpJF8w_TwwGYqUaTsjaKc1s7B7Jio-NdqWH6xrKDAYk53KjdehPqMNQJJEr5pM8ijpyXvvdtGUBrwgyrrOlVgoMqGwjUbk2LN7PVF3U6U6mSfiyy4rRuer0uPkN5SPYcTuFkldUrwpz6AXFGb9tOVtt1Ds1z75qmGWRAQ7R3KsjIFZ2oD_15lcQamc-rz0ZGLfNIgKjCqOZkFyOgvRYPnYvEvqPUTJrrs0xVkiIjVmXTtjsSbJtzTQKVd6xcv83yVwclvp-NQ9_2aQW4wq46QVB6_Y2F_kn7bJWf2i1Lf-p3HnTeuMuuVcN3tZw_TJffI3BbKs38BrtubBE-Kom1x3qY3mR7Zu4y_syUJH9-i4Fh2oHiGW94xhXPuOIZJ57xhmdc84xXPPv57UfFMN5mGK8ZdpsdHb6cjyeWOZzDij0hciuUGNrB0E9EEoggljJ2PCk8GUpSaV0f3SQi4xfIopBOGEpniU4CTiRk6AuJAQzvsJ10neI-42Q5gYxsDP0gJvUIwcNYxCiWYA8R0ekzq5rMRWwq16sDVM4WZMFqHBaEw6LGoc-e1v03Zc2Wv_Z8XGGzILGqfGWQ4rrIqLMgU2Fo-_T2uyVW9VgVyH0WdFCsO6iS7d2WdHWiS7cbgt279JP32W7z13rAdvJtgQ9JLc7lI03WXwaYvT8
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=TICAM-1%2FTRIF+associates+with+Act1+and+suppresses+IL-17+receptor%E2%80%93mediated+inflammatory+responses&rft.jtitle=Life+science+alliance&rft.au=Miyashita%2C+Yusuke&rft.au=Kouwaki%2C+Takahisa&rft.au=Tsukamoto%2C+Hirotake&rft.au=Okamoto%2C+Masaaki&rft.date=2022-02-01&rft.pub=Life+Science+Alliance+LLC&rft.eissn=2575-1077&rft.volume=5&rft.issue=2&rft_id=info:doi/10.26508%2Flsa.202101181&rft_id=info%3Apmid%2F34819358&rft.externalDocID=PMC8616538
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2575-1077&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2575-1077&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2575-1077&client=summon